These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7494608)

  • 1. Current Status of Mineral and Bone Disorders in Transplant Recipients.
    Elder GJ
    Transplantation; 2023 Oct; 107(10):2107-2119. PubMed ID: 36788445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone and Mineral Disease in Kidney Transplant Recipients.
    Khairallah P; Nickolas TL
    Clin J Am Soc Nephrol; 2022 Jan; 17(1):121-130. PubMed ID: 34127484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mixed uremic osteodystrophy: an ill-described common bone pathology in patients with chronic kidney disease.
    Elkhouli E; Nagy E; Santos CGS; Barreto FC; Chaer J; Jorgetti V; El-Husseini A
    Osteoporos Int; 2023 Dec; 34(12):2003-2012. PubMed ID: 37658999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of p53, Ki67, epidermal growth factor receptor, transforming growth-factorα, and p21 in primary and secondary hyperparathyroidism.
    Paydas S; Acikalim A; Kaya B; Bicer BH; Ulker M; Demircan O; Uguz A; Balal M; Sakman G; Sertdemir Y; Karaer R; Altun E
    Indian J Endocrinol Metab; 2014 Nov; 18(6):826-30. PubMed ID: 25364678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis.
    Zhang Q; Li M; You L; Li H; Ni L; Gu Y; Hao C; Chen J
    PLoS One; 2012; 7(10):e48070. PubMed ID: 23133549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclooxygenase 2 promotes parathyroid hyperplasia in ESRD.
    Zhang Q; Qiu J; Li H; Lu Y; Wang X; Yang J; Wang S; Zhang L; Gu Y; Hao CM; Chen J
    J Am Soc Nephrol; 2011 Apr; 22(4):664-72. PubMed ID: 21335517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activator protein 2alpha mediates parathyroid TGF-alpha self-induction in secondary hyperparathyroidism.
    Arcidiacono MV; Cozzolino M; Spiegel N; Tokumoto M; Yang J; Lu Y; Sato T; Lomonte C; Basile C; Slatopolsky E; Dusso AS
    J Am Soc Nephrol; 2008 Oct; 19(10):1919-28. PubMed ID: 18579641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone mineral density and bone turnover markers in children with chronic renal failure.
    Bakr AM
    Pediatr Nephrol; 2004 Dec; 19(12):1390-3. PubMed ID: 15517415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Renal osteodystrophy (2): its treatment in renal insufficiency before dialysis].
    Hottelart C; Bako G; Oprisiu R; Georgita A; Presne C; Sarraj A; Morinière P; el Esper N; Fournier A
    Nephrologie; 2000; 21(6):275-82. PubMed ID: 11117106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal osteodystrophy: pathogenesis and management.
    Gonzalez EA; Martin KJ
    Nephrol Dial Transplant; 1995; 10 Suppl 3():13-21. PubMed ID: 7494608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
    Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention and treatment of renal osteodystrophy in children with chronic renal insufficiency and end-stage renal disease.
    Sanchez CP
    Semin Nephrol; 2001 Sep; 21(5):441-50. PubMed ID: 11559885
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.